Israeli venture fund closes with $50 million:
This article was originally published in Clinica
Executive Summary
Israeli venture capital fund Vitalife has just closed its first fund, worth $50m. Investors include Boston Scientific, HarbourVest Partners and Discount Capital Markets and Investments. Specialising in life sciences, Vitalife's portfolio consists of companies based in Israel or with links to Israel. They include MediGuide, which is developing electro-magnetic technology for guiding devices in the body, and SightLine, which specialises in video endoscopy for minimally invasive procedures.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.